Vericel VCEL Business Segments
| Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | ||
|---|---|---|---|---|---|---|
| Product sales, net by Product | ||||||
| Biopsy kits | $606K-15.5% | $717K+10.0% | $652K+1.6% | $642K+7.7% | $596K+5.3% | |
| Epicel | $10.89M+34.2% | $8.11M-21.8% | $10.38M+20.4% | $8.61M+73.5% | $4.96M-17.5% | |
| M A C I Implants and kits | $56.4M-32.9% | $84.09M+51.1% | $55.66M+4.1% | $53.46M+15.5% | $46.3M-32.3% | |
| MACI implants, kits, and instruments | $41.51M-38.2% | $67.15M+63.4% | $41.09M+4.2% | $39.43M+23.9% | $31.84M-38.3% |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- How does Vericel break its business down?
- Vericel (VCEL) reports product sales, net by product across 4 parts — Biopsy kits, Epicel, M A C I Implants and kits and MACI implants, kits, and instruments. Each is extracted from the segment footnotes and tracked over time.
- Where does Vericel's segment data come from?
- Segment breakdowns are pulled from the segment footnotes in Vericel's SEC filings (the XBRL dimensional tags), so every line ties back to a reported figure. Switch between quarterly, annual, and TTM, or open any segment for its full history.
